2024-10-29-上交所-杭州天目山药业股份有限公司2024年第三季度报告_15页_354kb

Hangzhou Tianmu Mountain Pharmaceutical Co., Ltd.'s 2024 Q3 report shows mixed financial performance with substantial revenue growth but declining net profit. The company's revenue increased by 85.28% compared to the second quarter, reaching RMB 65.13 million for Q3, while net profit attributable to shareholders was RMB 14.805 million, reflecting a decline year-over-year due to expenses and operational factors. Financial indicators such as assets and cash flow highlight challenges, with negative operating cash flow and net losses in Q3.

Key business activities included progress in drug development, such as the successful一致性评价 for amoxicillin-clavulanate potassium and several drug registrations, alongside potential financial guarantees for subsidiaries. Shareholder information revealed ownership concentrations, with the top five shareholders holding significant stakes, and events like the pending non公开发行 and a planned EGM increase by key shareholders noted.

Over the past six months, these activities were influenced by regulatory developments and affiliate actions, all aimed at bolstering company resilience and future growth prospects.